What changed
$ECL — Provides water, hygiene, and infection prevention solutions.
🎯 Q1 FY26 | Rev $4B | EPS $1.70 vs $1.70 🟢 | Margin 15.3%
💡 Consensus expects steady mid-single-digit organic growth and margin expansion from Ecolab's recurring service model. The market may be underestimating the pace of margin recovery as volume leverage and pricing stickiness improve, but the 0.16% EPS beat is too small to signal a material inflection.
🏢 Business Quality: 8/10 | Valuation: fair
📉 Reward/Risk: Upside 8% to $278 (30x FY2026 EPS of $9.25) vs downside 12% to $226 (25x FY2026 EPS). Ratio: 0.67x, unfavorable.
🔮 Catalyst: Q2 2026 earnings report (late July 2026). Watch: reported EPS vs $2.02-$2.12 guidance range. Failure signal: EPS below $2.02 or organic sales growth <3%.
💰 Entry: Current price $256.99 is not attractive. Ideal entry: $230-$240 (25-27x forward EPS) to build a margin of safety.
Also in play: $EQNR $CVX $XOM $SHEL $TTE